- 1 in 5 Americans Has an STD: CDC
- For Women Who’ve Miscarried, Aspirin Before, During Pregnancy Could Improve Outcomes
- AHA News: Reversing Prediabetes Linked to Fewer Heart Attacks, Strokes
- Just 2% of U.S. Teens Eat Recommended Amount of Veggies
- Biden Sets New Goal of 1.5 Million COVID Vaccinations a Day
- Health Highlights: Jan. 26, 2021
- How Dangerous Is Coronavirus to the Middle-Aged?
- Healthy Eating Could Delay Onset of Parkinson’s Disease
- Midday Nap Could Leave You Smarter: Study
- Kids Aren’t Scared by Medical Workers’ PPE, Study Finds
Spiriva Inhaler Approved To Reduce Flares of COPD
FRIDAY, Dec. 18The U.S. Food and Drug Administration has expanded approval for the Spiriva Handihaler (tiotropium bromide inhalation powder) to include reducing symptoms during flares of chronic obstructive pulmonary disease (COPD), makers Boehringer Ingleheim Pharmaceuticals and Pfizer said.
COPD is a broad term for respiratory disorders that include chronic bronchitis and emphysema.
The Spiriva Handihaler, first FDA-approved in 2004, is already sanctioned as a once-daily maintenance treatment for COPD-related problems, including cough, wheezing or difficulty breathing,
COPD leads to the deaths of an estimated 120,000 Americans annually, the drug makers said in a news release.
More information
The U.S. National Heart Lung and Blood Institute has more about COPD.
Source: HealthDay
